Oncolytics Biotech announced that its investigational immunotherapy pelareorep showed a median response duration of 19.5 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, significantly exceeding the historical 4-6 month benchmark. The combination therapy also achieved a 33% objective response rate, tripling standard care outcomes. The company is engaging with the FDA to pursue accelerated approval based on these promising results and is currently enrolling patients in a Phase 2 trial. This development addresses a critical unmet need in a difficult-to-treat cancer population, potentially offering a new effective treatment option.
ISS has secured a seven-year contract with West Sussex County Council to deliver around 25,000 nutritious school meals daily to primary schools starting Q3 2026. The contract, valued at about DKK 100 million annually, emphasizes inclusivity and high ...
Roche has introduced the Liver Disease Panel, the first comprehensive set of certified algorithms designed to improve the detection and management of chronic liver disease (CLD). This panel includes LiverPRO, an algorithm that uses routine blood mark...
TGS ASA has secured a large 4D streamer contract offshore Angola, set to begin data acquisition in early July 2026 and last about eight months. This contract strengthens TGS's strategic presence in Africa and ensures vessel utilization into early 202...
argenx, a global immunology company focused on autoimmune diseases, announced its management team will present at two key investor conferences in June: the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Hea...
Capgemini unveiled its 2028 strategic plan focusing on leveraging AI agent technology to drive business transformation for large enterprises. The company aims for a 5.5% to 7.5% annual revenue growth from 2025 to 2028, with about 2 points from merger...
